T
TRIMTECH Therapeutics
Developing small molecule degraders targeting protein aggregates for neurodegenerative and inflammatory disorders
About TRIMTECH Therapeutics
TRIMTECH Therapeutics is a Cambridge biotech developing orally active small-molecule targeted protein degraders that selectively remove toxic protein aggregates while sparing functional monomeric forms, aimed at neurodegenerative and inflammatory disease. Founded in 2023 on TRIM21 E3-ligase research from Leo James (MRC LMB) and Will McEwan (UK DRI / University of Cambridge), with Cambridge Innovation Capital and SV Health Investors’ Dementia Discovery Fund and entrepreneur-in-residence Damian Crowther among early backers, the company advances proprietary TRIMTAC and TRIMGLUE platforms for CNS-penetrant degraders under CEO Dr Nicki Thompson. In June 2026 TRIMTECH raised an additional €12 million ($14 million) Seed extension led by Johnson & Johnson Innovation – JJDC and BGF, bringing the Seed round to €41 million ($47 million) with prior investors including CIC, DDF, M Ventures, Pfizer Ventures, Eli Lilly, MPH, Cambridge Enterprise Ventures and Start Codon; JJDC and BGF joined the board as non-executive directors. Sources: EU-Startups 23 Jun 2026; company / BioSpace.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- Cambridge, United Kingdom
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 56.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Alzheimers Disease, Spinout, Biotech and Pharma, uk is8 life sciences, UKSU, UKSU2010, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Jun 2026 | $14M | $56M | MP Healthcare Venture Management · Johnson & Johnson Innovation · Johnson & Johnson Innovative Medicine · Dementia Discovery Fund | ↗ |
| EARLY VCOther financing | Mar 2026 | $11M | $152M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for TRIMTECH Therapeutics is 2.2K monthly website visits, up 249.2% over the last three months. TRIMTECH Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed14 investors entered at this stage
Cambridge Innovation Capital
MP Healthcare Venture Management
Pfizer
Eli Lilly
Start Codon
M Ventures
SV Health Investors
Johnson & Johnson Innovation
Johnson & Johnson Innovative Medicine
Dementia Discovery Fund
Business Growth Fund
DDF- PVPfizer Ventures
Cambridge Enterprise Ventures
Other known investors3 additional known investors
KU Leuven
MRC Laboratory of Molecular Biology
University of Cambridge
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TRIMTECH Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TRIMTECH Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.